Dalpiciclib
- Generic Name
- Dalpiciclib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast CancerAdvanced Breast Cancer
- Interventions
- Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT05949541
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
A Phase â… b/â…¡ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Phase 1
Not yet recruiting
- Conditions
- HER2 Low Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05792410
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 145
- Registration Number
- NCT05759572
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05759546
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Phase 2
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 32
- Registration Number
- NCT05724355
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Phase 2
Recruiting
- Conditions
- Luminal B/HER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT05640778
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: Gonadotropin-releasing hormone agonist
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- HER2-negative Breast CancerAdvanced Breast CancerBreast NeoplasmBreast CancerHormone Receptor Positive Tumor
- Interventions
- Drug: AKT inhibitorDrug: CarrelizumabDrug: SHR-1167Drug: TPCDrug: SHR-6209
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study
Phase 1
Not yet recruiting
- Conditions
- HR+/HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05586841
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath